Prostamax

Graded D: human numbers exist only as unpublished examples in the developers' patent, comparable to case reports, never peer-reviewed or tested by anyone else.

Strengths: 20 mg
Also known as: KEDP, Lys-Glu-Asp-Pro, prostate tetrapeptide
Molecule: Synthetic 4-amino-acid peptide
Formula: C20H33N5O9
Mol. weight: 487.50 g/mol
CAS: 473578-47-1 (catalog listing)
Sequence: Lys-Glu-Asp-Pro

Origin

Developed by Khavinson's institute in St. Petersburg as a simpler synthetic stand-in for Prostatilen (Samprost), an older cattle-prostate extract used clinically in Russia.

How it works

Not established. The developers' general theory is that ultrashort peptides enter cell nuclei and adjust gene expression; for KEDP the evidence is limited to DNA-stability experiments and computer docking. How it would reach the prostate selectively has not been shown.

What the research shows

Research is limited to the developers' patent: rats with induced chronic prostatitis showed a modestly better tissue score, old rats showed small shifts in oxidative-stress markers, and chicken-embryo bladder tissue grew more. The patent also describes two small human groups (chronic prostatitis and BPH) without control results, randomization, blinding or statistics. Clinical reports on the parent extract do not apply to this peptide. There are no independent studies and no human pharmacokinetic or PSA data.

Key studies

EP1353939B1 patent (Khavinson et al.), 2004 Rat prostatitis and small human examples; no controls or statistics reported.
Khavinson et al., Molecules 2021 Review of the group's gene-regulation theory, including KEDP DNA-binding experiments.
Khavinson et al., Int J Mol Sci 2022 Docking predicted KEDP does not bind the LAT1 transporter well.

Safety findings

No human safety studies; the patent reports no adverse effects but gives no adverse-event data. Rodents in high-exposure single and repeated studies showed no reported toxicity, but subacute results were not detailed. Effects in people with prostate cancer are unknown.

Regulatory status

Not FDA-approved for any use and not on any FDA compounding list checked, so it cannot lawfully be compounded. Not named on the 2026 WADA List; with no government approval anywhere it most likely falls under S0.

Catalog notes

Offered in 20 mg. The published certificate (lot PROS20-0318, 99.9% purity, COA3398) is labeled 10 mg, so check with support for a 20 mg certificate. Follow the storage stated on the label and certificate.